{"title":"Reply to the letter regarding the article 'Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?'","authors":"Guillaume Baudry, Marco Metra, Clément Delmas","doi":"10.1002/ejhf.3489","DOIUrl":"https://doi.org/10.1002/ejhf.3489","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142566885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The patterns and changes of heart failure treatment in the last years of life still need further study. Letter regarding the article 'Heart failure treatment in the last years of life: A nationwide study of 364 000 individuals'.","authors":"Yuqin Zhao, Zhenglin Shen","doi":"10.1002/ejhf.3508","DOIUrl":"https://doi.org/10.1002/ejhf.3508","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yogesh N.V. Reddy, Javed Butler, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Giuseppe M.C. Rosano, Clara I. Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad
In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.
{"title":"Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial","authors":"Yogesh N.V. Reddy, Javed Butler, Kevin J. Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin A. Ezekowitz, Carolyn S.P. Lam, Eldrin F. Lewis, JoAnn Lindenfeld, Ciaran J. McMullan, Robert J. Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Giuseppe M.C. Rosano, Clara I. Saldarriaga, Michele Senni, James Udelson, Adriaan A. Voors, Faiez Zannad","doi":"10.1002/ejhf.3501","DOIUrl":"https://doi.org/10.1002/ejhf.3501","url":null,"abstract":"In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"130 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142541572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Felix Lindberg, Lina Benson, Ulf Dahlström, Lars H Lund, Gianluigi Savarese
Aims: Data from US have shown a reversal in the improvement of heart failure (HF)-related mortality over the last ~10 years. It is unknown whether these trends generalize to European universal healthcare systems. We assessed temporal trends in (i) HF-related mortality in the overall national population; and (ii) all-cause mortality following an incident HF diagnosis, overall and stratified by ejection fraction (EF), in Sweden between 1997 and 2022.
Methods and results: Annual mortality rates with a HF diagnosis as underlying cause were extracted from the Cause of Death Register. All-cause mortality following incident HF was assessed in two HF cohorts derived from the National Patient Register (NPR) and the Swedish HF Registry (SwedeHF). Temporal trends were presented as average annual percentage change (AAPC). Between 1997 and 2022, age-adjusted HF-related mortality in the general population declined from 33.4 to 23.8 per 100 000 individuals (AAPC -2.15%, p < 0.001). In the HF cohort from NPR (n = 423 092), all-cause mortality at 1, 3, and 5 years following a first diagnosis of HF was 25%, 46%, and 58%, respectively, in 2022; 1-year mortality declined (AAPC -1.10%, p < 0.001) over time regardless of age or sex. In SwedeHF (n = 63 753), the decline in 1-year mortality was less steep with increasing EF (AAPC -2.64%, p < 0.001; -2.30%, p = 0.062; and -2.16%, p = 0.032 in EF <40%, 40-49%, and ≥50%, respectively).
Conclusions: Heart failure-related mortality has declined over the last ~25 years in Sweden. All-cause mortality in patients with HF has also declined, more in HF with reduced than preserved EF, mirroring the different availability of life-saving treatments across the EF spectrum.
{"title":"Trends in heart failure mortality in Sweden between 1997 and 2022.","authors":"Felix Lindberg, Lina Benson, Ulf Dahlström, Lars H Lund, Gianluigi Savarese","doi":"10.1002/ejhf.3506","DOIUrl":"https://doi.org/10.1002/ejhf.3506","url":null,"abstract":"<p><strong>Aims: </strong>Data from US have shown a reversal in the improvement of heart failure (HF)-related mortality over the last ~10 years. It is unknown whether these trends generalize to European universal healthcare systems. We assessed temporal trends in (i) HF-related mortality in the overall national population; and (ii) all-cause mortality following an incident HF diagnosis, overall and stratified by ejection fraction (EF), in Sweden between 1997 and 2022.</p><p><strong>Methods and results: </strong>Annual mortality rates with a HF diagnosis as underlying cause were extracted from the Cause of Death Register. All-cause mortality following incident HF was assessed in two HF cohorts derived from the National Patient Register (NPR) and the Swedish HF Registry (SwedeHF). Temporal trends were presented as average annual percentage change (AAPC). Between 1997 and 2022, age-adjusted HF-related mortality in the general population declined from 33.4 to 23.8 per 100 000 individuals (AAPC -2.15%, p < 0.001). In the HF cohort from NPR (n = 423 092), all-cause mortality at 1, 3, and 5 years following a first diagnosis of HF was 25%, 46%, and 58%, respectively, in 2022; 1-year mortality declined (AAPC -1.10%, p < 0.001) over time regardless of age or sex. In SwedeHF (n = 63 753), the decline in 1-year mortality was less steep with increasing EF (AAPC -2.64%, p < 0.001; -2.30%, p = 0.062; and -2.16%, p = 0.032 in EF <40%, 40-49%, and ≥50%, respectively).</p><p><strong>Conclusions: </strong>Heart failure-related mortality has declined over the last ~25 years in Sweden. All-cause mortality in patients with HF has also declined, more in HF with reduced than preserved EF, mirroring the different availability of life-saving treatments across the EF spectrum.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna Dieden, Nicolas Girerd, Filip Ottosson, John Molvin, Manan Pareek, Olle Melander, Erasmus Bachus, Lennart Råstam, Ulf Lindblad, Bledar Daka, Margrét Leósdóttir, Peter M. Nilsson, Michael H. Olsen, Andrew L. Clark, John G.F. Cleland, Christian Delles, Arantxa González, Zohra Lamiral, Kevin Duarte, Patrick Rossignol, Faiez Zannad, Petri Gudmundsson, Amra Jujić, Martin Magnusson
Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.
{"title":"Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohorts","authors":"Anna Dieden, Nicolas Girerd, Filip Ottosson, John Molvin, Manan Pareek, Olle Melander, Erasmus Bachus, Lennart Råstam, Ulf Lindblad, Bledar Daka, Margrét Leósdóttir, Peter M. Nilsson, Michael H. Olsen, Andrew L. Clark, John G.F. Cleland, Christian Delles, Arantxa González, Zohra Lamiral, Kevin Duarte, Patrick Rossignol, Faiez Zannad, Petri Gudmundsson, Amra Jujić, Martin Magnusson","doi":"10.1002/ejhf.3502","DOIUrl":"https://doi.org/10.1002/ejhf.3502","url":null,"abstract":"Biomarkers associated with asymptomatic ventricular dysfunction might improve risk stratification and identify pathways leading to heart failure (HF). We explored the association between proteomic biomarkers and left ventricular hypertrophy (LVH), diastolic dysfunction (DD) and incident HF in three population-based cohorts.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"2 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142519444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shelley Zieroth, Clara Inés Saldarriaga Giraldo, Fausto Pinto, Stefan D. Anker, William T. Abraham, John J. Atherton, Javed Butler, Vijay Chopra, Andrew J.S. Coats, Veronica Dean, Gerasimos Filippatos, Jose Luis Zamorano, Yuhui Zhang, Richard B. Weiskopf, Yann Colardelle
AimsClinical practice guidelines are commonly written by professional societies in high‐income countries (HIC) with limited anticipation of implementation obstacles in other environments. We used heart failure (HF) guidelines as a paradigm to examine this concern, by conducting a survey to understand clinicians' ability to implement HF guidelines and their perceptions of the current HF guideline applicability in low‐ and middle‐income countries (LMIC).Methods and resultsAn online survey of physicians in the database of the Translational Medicine Academy who treat HF patients was offered by email from 5 October to 27 November 2023, inquiring of participants' demographic information, experience, and views of HF guidelines as related to their practice. Of 2622 participating clinicians, 1592 partially completed, and an additional 1030 fully completed the survey. Participants were from 138 countries; 668 practiced in HIC, and 1954 in LMIC. Those from LMIC regarded HF guidelines to be less applicable in their country than did those from HIC (p = 0.0002). Of all those responding, 75.3% indicated that it was somewhat or mostly true that the HF guidelines were mostly applicable to HIC. Those from LMIC, but not HIC indicated that the greatest implementation obstacle was that the guidelines were for HIC (51.3% vs. 43.1%; p = 0.0387). A significantly higher proportion of respondents from LMIC indicated that resources for caring for their patients were somewhat or mostly limiting in most cases, than did those in HIC (41.6% vs. 32.5%, p = 0.0068).ConclusionThis survey examined the widely‐held thought that HF guidelines are broadly applicable to all regions of the world, concluding that such a perception is incorrect. Clinicians from LMIC view the absence of consideration of local resource limitations as the greatest obstacle for guideline implementation. The results regarding HF guidelines likely also have implications for other guidelines and resultant patient outcomes.
{"title":"Applicability of heart failure clinical practice guidelines in low‐ and middle‐income countries","authors":"Shelley Zieroth, Clara Inés Saldarriaga Giraldo, Fausto Pinto, Stefan D. Anker, William T. Abraham, John J. Atherton, Javed Butler, Vijay Chopra, Andrew J.S. Coats, Veronica Dean, Gerasimos Filippatos, Jose Luis Zamorano, Yuhui Zhang, Richard B. Weiskopf, Yann Colardelle","doi":"10.1002/ejhf.3485","DOIUrl":"https://doi.org/10.1002/ejhf.3485","url":null,"abstract":"AimsClinical practice guidelines are commonly written by professional societies in high‐income countries (HIC) with limited anticipation of implementation obstacles in other environments. We used heart failure (HF) guidelines as a paradigm to examine this concern, by conducting a survey to understand clinicians' ability to implement HF guidelines and their perceptions of the current HF guideline applicability in low‐ and middle‐income countries (LMIC).Methods and resultsAn online survey of physicians in the database of the Translational Medicine Academy who treat HF patients was offered by email from 5 October to 27 November 2023, inquiring of participants' demographic information, experience, and views of HF guidelines as related to their practice. Of 2622 participating clinicians, 1592 partially completed, and an additional 1030 fully completed the survey. Participants were from 138 countries; 668 practiced in HIC, and 1954 in LMIC. Those from LMIC regarded HF guidelines to be less applicable in their country than did those from HIC (<jats:italic>p</jats:italic> = 0.0002). Of all those responding, 75.3% indicated that it was somewhat or mostly true that the HF guidelines were mostly applicable to HIC. Those from LMIC, but not HIC indicated that the greatest implementation obstacle was that the guidelines were for HIC (51.3% vs. 43.1%; <jats:italic>p</jats:italic> = 0.0387). A significantly higher proportion of respondents from LMIC indicated that resources for caring for their patients were somewhat or mostly limiting in most cases, than did those in HIC (41.6% vs. 32.5%, <jats:italic>p</jats:italic> = 0.0068).ConclusionThis survey examined the widely‐held thought that HF guidelines are broadly applicable to all regions of the world, concluding that such a perception is incorrect. Clinicians from LMIC view the absence of consideration of local resource limitations as the greatest obstacle for guideline implementation. The results regarding HF guidelines likely also have implications for other guidelines and resultant patient outcomes.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"35 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reply to the letter regarding the article ‘Predictors of the efficacy of His bundle pacing in patients with a prolonged PR interval: A stratified analysis of the HOPE-HF randomized controlled trial’","authors":"Nandita Kaza, Zachary Whinnett, Daniel Keene","doi":"10.1002/ejhf.3488","DOIUrl":"https://doi.org/10.1002/ejhf.3488","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"60 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Markus S. Anker, Jan Porthun, Antoni Bayes-Genis, Sophie Van Linthout
Click on the article title to read more.
点击文章标题阅读更多内容。
{"title":"Time for differential weight management in heart failure","authors":"Markus S. Anker, Jan Porthun, Antoni Bayes-Genis, Sophie Van Linthout","doi":"10.1002/ejhf.3495","DOIUrl":"https://doi.org/10.1002/ejhf.3495","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"20 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Henry Oluwasefunmi Savage, Kyle McBeath, Janine Hogan, Lynn MacKay-Thomas, Lisa Anderson, Andy Smith, Joanne Bateman, Poppy Brooks, Antoni Bayes-Genis, Amanda Vest, John Teerlink, Giuseppe Rosano, Roy S Gardner
<h2> Introduction</h2> <p>We are at a crucial point in time for those with cardiovascular diseases such as heart failure (HF).</p> <p>An estimated 64.3 million people are living with HF worldwide.<span><sup>1</sup></span> In developed countries, the prevalence of diagnosed HF is estimated at 1–2% of the adult population,<span><sup>2, 3</sup></span> and with factors such as our expanding ageing population, figures are set to double by 2040 (<i>Figure</i> 1).</p> <figure><picture> <source media="(min-width: 1650px)" srcset="/cms/asset/55fc4055-b350-4620-97e9-9cded4b1bd1d/ejhf3496-fig-0001-m.jpg"/><img alt="Details are in the caption following the image" data-lg-src="/cms/asset/55fc4055-b350-4620-97e9-9cded4b1bd1d/ejhf3496-fig-0001-m.jpg" loading="lazy" src="/cms/asset/fa851e27-81a7-4063-b6d0-681db819b9f1/ejhf3496-fig-0001-m.png" title="Details are in the caption following the image"/></picture><figcaption> <div><strong>Figure 1<span style="font-weight:normal"></span></strong><div>Open in figure viewer<i aria-hidden="true"></i><span>PowerPoint</span></div> </div> <div>Projected total number of diagnosed cases for the 10 conditions with the highest impact on healthcare use and mortality among those aged 30 years and older, including demographic changes, England, 2019 and projected for 2040. Attrib. Health Foundation REAL Centre.<span><sup>13</sup></span> Analysis of linked healthcare records and mortality data conducted by the REAL Centre and the University of Liverpool. Red shaded bars represent uncertainty intervals. COPD, chronic obstructive pulmonary disease.</div> </figcaption> </figure> <p>Heart failure is a final common pathway for almost all cardiovascular diseases, but also a significant cause of mortality across the wider cardio-renal-metabolic spectrum. Over 90% of those who are diagnosed with HF are living with at least one other long-term condition<span><sup>4</sup></span> such as diabetes, kidney disease, high blood pressure, chronic obstructive pulmonary disease and depression. From epidemiology to pathophysiology, there is a large multi-specialty and multi-disciplinary overlap.</p> <p>Diagnosing HF, however, remains a challenge. Eighty per cent of patients receive their diagnosis during an emergency admission.<span><sup>5</sup></span> This is even though up to 40% of these patients had symptoms many months prior to that admission which should have triggered an earlier assessment.<span><sup>5</sup></span> Delayed diagnosis has a significant impact on mortality and spending. One in three of these patients do not survive up to 1 year and inpatient costs are a significant driver of expenditure for HF care, which itself accounts for almost 2% (€2.3 billion) of the entire National Health Service (NHS) budget.<span><sup>6</sup></span></p> <p>Many patients with HF remain undetected and undiagnosed. In the UK alone, it is estimated that around 400 000 people who have HF remain without a documented diagnosis. These patients are disproportionate
{"title":"The 25in25 initiative: A novel transformative project to reduce mortality due to heart failure by 25% in the next 25 years","authors":"Henry Oluwasefunmi Savage, Kyle McBeath, Janine Hogan, Lynn MacKay-Thomas, Lisa Anderson, Andy Smith, Joanne Bateman, Poppy Brooks, Antoni Bayes-Genis, Amanda Vest, John Teerlink, Giuseppe Rosano, Roy S Gardner","doi":"10.1002/ejhf.3496","DOIUrl":"https://doi.org/10.1002/ejhf.3496","url":null,"abstract":"<h2> Introduction</h2>\u0000<p>We are at a crucial point in time for those with cardiovascular diseases such as heart failure (HF).</p>\u0000<p>An estimated 64.3 million people are living with HF worldwide.<span><sup>1</sup></span> In developed countries, the prevalence of diagnosed HF is estimated at 1–2% of the adult population,<span><sup>2, 3</sup></span> and with factors such as our expanding ageing population, figures are set to double by 2040 (<i>Figure</i> 1).</p>\u0000<figure><picture>\u0000<source media=\"(min-width: 1650px)\" srcset=\"/cms/asset/55fc4055-b350-4620-97e9-9cded4b1bd1d/ejhf3496-fig-0001-m.jpg\"/><img alt=\"Details are in the caption following the image\" data-lg-src=\"/cms/asset/55fc4055-b350-4620-97e9-9cded4b1bd1d/ejhf3496-fig-0001-m.jpg\" loading=\"lazy\" src=\"/cms/asset/fa851e27-81a7-4063-b6d0-681db819b9f1/ejhf3496-fig-0001-m.png\" title=\"Details are in the caption following the image\"/></picture><figcaption>\u0000<div><strong>Figure 1<span style=\"font-weight:normal\"></span></strong><div>Open in figure viewer<i aria-hidden=\"true\"></i><span>PowerPoint</span></div>\u0000</div>\u0000<div>Projected total number of diagnosed cases for the 10 conditions with the highest impact on healthcare use and mortality among those aged 30 years and older, including demographic changes, England, 2019 and projected for 2040. Attrib. Health Foundation REAL Centre.<span><sup>13</sup></span> Analysis of linked healthcare records and mortality data conducted by the REAL Centre and the University of Liverpool. Red shaded bars represent uncertainty intervals. COPD, chronic obstructive pulmonary disease.</div>\u0000</figcaption>\u0000</figure>\u0000<p>Heart failure is a final common pathway for almost all cardiovascular diseases, but also a significant cause of mortality across the wider cardio-renal-metabolic spectrum. Over 90% of those who are diagnosed with HF are living with at least one other long-term condition<span><sup>4</sup></span> such as diabetes, kidney disease, high blood pressure, chronic obstructive pulmonary disease and depression. From epidemiology to pathophysiology, there is a large multi-specialty and multi-disciplinary overlap.</p>\u0000<p>Diagnosing HF, however, remains a challenge. Eighty per cent of patients receive their diagnosis during an emergency admission.<span><sup>5</sup></span> This is even though up to 40% of these patients had symptoms many months prior to that admission which should have triggered an earlier assessment.<span><sup>5</sup></span> Delayed diagnosis has a significant impact on mortality and spending. One in three of these patients do not survive up to 1 year and inpatient costs are a significant driver of expenditure for HF care, which itself accounts for almost 2% (€2.3 billion) of the entire National Health Service (NHS) budget.<span><sup>6</sup></span></p>\u0000<p>Many patients with HF remain undetected and undiagnosed. In the UK alone, it is estimated that around 400 000 people who have HF remain without a documented diagnosis. These patients are disproportionate","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"98 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paul W. Foley, Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, Philip A. Kalra, Ian Squire, Philip Campbell, Callum Chapman, Patrick Donnelly, Fraser Graham, Andrew Hannah, Ninian N. Lang, Iain Matthews, Stephen J. Leslie, Pierpaolo Pellicori, Sue Piper, Robin Ray, Hernry O. Savage, Chales Spencer, John Walsh, Yuk-Ki Wong, Ian Ford
Concerns exist that intravenous (IV) iron might increase the risk of infections. The IRONMAN trial provided an opportunity to investigate whether giving IV ferric derisomaltose (FDI) to patients with heart failure and iron deficiency alters the rate of hospitalization or death due to infections.
{"title":"Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial","authors":"Paul W. Foley, Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, Philip A. Kalra, Ian Squire, Philip Campbell, Callum Chapman, Patrick Donnelly, Fraser Graham, Andrew Hannah, Ninian N. Lang, Iain Matthews, Stephen J. Leslie, Pierpaolo Pellicori, Sue Piper, Robin Ray, Hernry O. Savage, Chales Spencer, John Walsh, Yuk-Ki Wong, Ian Ford","doi":"10.1002/ejhf.3504","DOIUrl":"https://doi.org/10.1002/ejhf.3504","url":null,"abstract":"Concerns exist that intravenous (IV) iron might increase the risk of infections. The IRONMAN trial provided an opportunity to investigate whether giving IV ferric derisomaltose (FDI) to patients with heart failure and iron deficiency alters the rate of hospitalization or death due to infections.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"4 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：